다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Therapeutic advances in gastroenterology, v.3 no.4, 2010년, pp.259 - 267
Peck-Radosavljevic, Markus (Department of Gastroenterology and Hepatology, Medical University of Vienna, Wä)
AI-Helper
Medical therapies have entered center stage in the treatment of hepatocellular carcinoma (HCC) little more than a year after the positive results of a large phase III trial of sorafenib showed a clear survival benefit with sorafenib, a targeted agent, in this setting. Even though this marks a break...
Abou Alfa, G.K., Johnson, P., Knox, J., Lacava, J., Leung, T., Mori, A., Leberre, M.A., Voliotis, D., Saltz, L.. 3500 ORAL Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. EJC supplements, vol.5, no.4, 259-259.
Abou-Alfa, Ghassan K., Schwartz, Lawrence, Ricci, Sergio, Amadori, Dino, Santoro, Armando, Figer, Arie, De Greve, Jacques, Douillard, Jean-Yves, Lathia, Chetan, Schwartz, Brian, Taylor, Ian, Moscovici, Marius, Saltz, Leonard B.. Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.24, no.26, 4293-4300.
Asnacios, Amani, Fartoux, Laetitia, Romano, Olivier, Tesmoingt, Chloe, Louafi S, Samy, Mansoubakht, Touraj, Artru, Pascal, Poynard, Thierry, Rosmorduc, Olivier, Hebbar, Mohamed, Taieb, Julien. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma : Results of a multicenter phase 2 study. Cancer, vol.112, no.12, 2733-2739.
J Clin Oncol Bolondi, L. A129 26 2008
Bruix, J., Llovet, J.M.. Major achievements in hepatocellular carcinoma. The Lancet, vol.373, no.9664, 614-616.
Bruix, Jordi, Sala, Margarita, Llovet, Josep M.. Chemoembolization for hepatocellular carcinoma. Gastroenterology, vol.127, no.5, S179-S188.
Bruix, Jordi, Sherman, Morris. Management of hepatocellular carcinoma. Hepatology : official journal of the American Association for the Study of Liver Diseases, vol.42, no.5, 1208-1236.
Cheng, A., Kang, Y., Chen, Z., Tsao, C., Qin, S., Kim, J., Burock, K., Zou, J., Voliotis, D., Guan, Z. Z.. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.26, no.15, 4509-4509.
Duran, Ignacio, Hotté, Sebastien J., Hirte, Holger, Chen, Eric X., MacLean, Martha, Turner, Sandra, Duan, Lixia, Pond, Gregory R., Lathia, Chetan, Walsh, Scott, Wright, John J., Dancey, Janet, Siu, Lillian L.. Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors. Clinical Cancer research : an official journal of the American Association for Cancer Research, vol.13, no.16, 4849-4857.
Faivre, S., Raymond, E., Boucher, E., Douillard, J., Lim, H.Y., Kim, J.S., Zappa, M., Lanzalone, S., Lin, X., DePrimo, S., Harmon, C., Ruiz-Garcia, A., Lechuga, M.J., Cheng, A.L.. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. The Lancet. Oncology, vol.10, no.8, 794-800.
Global Cancer Facts and Figures 2007 Garcia, M. 2007
Hilberg, Frank, Roth, Gerald J., Krssak, Martin, Kautschitsch, Susanna, Sommergruber, Wolfgang, Tontsch-Grunt, Ulrike, Garin-Chesa, Pilar, Bader, Gerd, Zoephel, Andreas, Quant, Jens, Heckel, Armin, Rettig, Wolfgang J.. BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy. Cancer research : the official organ of the American Association for Cancer Research, Inc, vol.68, no.12, 4774-4782.
Himmelsbach, K., Sauter, D., Baumert, T. F., Ludwig, L., Blum, H. E., Hildt, E.. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut: journal of the British Society of Gastroenterology, vol.58, no.12, 1644-1653.
Hurwitz, Herbert, Fehrenbacher, Louis, Novotny, William, Cartwright, Thomas, Hainsworth, John, Heim, William, Berlin, Jordan, Baron, Ari, Griffing, Susan, Holmgren, Eric, Ferrara, Napoleone, Fyfe, Gwen, Rogers, Beth, Ross, Robert, Kabbinavar, Fairooz. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. The New England journal of medicine, vol.350, no.23, 2335-2342.
Huynh, Hung, Ngo, Van Chanh, Fargnoli, Joseph, Ayers, Mark, Soo, Khee Chee, Koong, Heng Nung, Thng, Choon Hua, Ong, Hock Soo, Chung, Alexander, Chow, Pierce, Pollock, Pamela, Byron, Sara, Tran, Evelyn. Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma. Clinical Cancer research : an official journal of the American Association for Cancer Research, vol.14, no.19, 6146-6153.
Li, Zhen. Cell apoptosis and regeneration of hepatocellular carcinoma after transarterial chemoembolization. World journal of gastroenterology : WJG, vol.10, no.13, 1876-.
Lin, Albert Y., Fisher, George A., So, Samuel, Tang, Christopher, Levitt, Lee. Phase II Study of Imatinib in Unresectable Hepatocellular Carcinoma. American journal of clinical oncology: cancer clinical trials, vol.31, no.1, 84-88.
Liu, Weitian, Makrauer, Frederick L., Qamar, Amir A., Jänne, Pasi A., Odze, Robert D.. Fulminant Hepatic Failure Secondary to Erlotinib. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol.5, no.8, 917-920.
Livraghi, Tito, Meloni, Franca, Di Stasi, Michele, Rolle, Emanuela, Solbiati, Luigi, Tinelli, Carmine, Rossi, Sandro. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?. Hepatology : official journal of the American Association for the Study of Liver Diseases, vol.47, no.1, 82-89.
Llovet, J M, Brú, C, Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification.. Seminars in liver disease, vol.19, no.3, 329-338.
Llovet, Josep M., Bruix, Jordi. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology : official journal of the American Association for the Study of Liver Diseases, vol.37, no.2, 429-442.
Llovet, Josep M., Bruix, Jordi. Novel advancements in the management of hepatocellular carcinoma in 2008. Journal of hepatology : the journal of the European Association for the Study of the Liver, vol.48, no.suppl1, S20-S37.
Llovet, Josep M., Di Bisceglie, Adrian M., Bruix, Jordi, Kramer, Barnett S., Lencioni, Riccardo, Zhu, Andrew X., Sherman, Morris, Schwartz, Myron, Lotze, Michael, Talwalkar, Jayant, Gores, Gregory J.. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. Journal of the National Cancer Institute: JNCI, vol.100, no.10, 698-711.
Llovet, Josep M., Ricci, Sergio, Mazzaferro, Vincenzo, Hilgard, Philip, Gane, Edward, Blanc, Jean-Frédéric, de Oliveira, Andre Cosme, Santoro, Armando, Raoul, Jean-Luc, Forner, Alejandro, Schwartz, Myron, Porta, Camillo, Zeuzem, Stefan, Bolondi, Luigi, Greten, Tim F., Galle, Peter R., Seitz, Jean-François, Borbath, Ivan, Häussinger, Dieter, Giannaris, Tom, Shan, Minghua, Moscovici, Marius, Voliotis, Dimitris, Bruix, Jordi. Sorafenib in Advanced Hepatocellular Carcinoma. The New England journal of medicine, vol.359, no.4, 378-390.
Llovet, Josep M, Schwartz, Myron, Mazzaferro, Vincenzo. Resection and liver transplantation for hepatocellular carcinoma.. Seminars in liver disease, vol.25, no.2, 181-200.
Marelli, Laura, Stigliano, Rosa, Triantos, Christos, Senzolo, Marco, Cholongitas, Evangelos, Davies, Neil, Tibballs, Jonathan, Meyer, Tim, Patch, David W., Burroughs, Andrew K.. Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies. Cardiovascular and interventional radiology, vol.30, no.1, 6-25.
Mathurin,, Rixe,, Carbonell,, Bernard,, Cluzel,, Bellin,, Khayat,, Opolon,, Poynard,. Review article: overview of medical treatments in unresectable hepatocellular carcinoma-an impossible meta‐analysis?. Alimentary pharmacology & therapeutics, vol.12, no.2, 111-126.
Pàez-Ribes, Marta, Allen, Elizabeth, Hudock, James, Takeda, Takaaki, Okuyama, Hiroaki, Viñals, Francesc, Inoue, Masahiro, Bergers, Gabriele, Hanahan, Douglas, Casanovas, Oriol. Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer cell, vol.15, no.3, 220-231.
Peck-Radosavljevic, Markus, Greten, Tim F., Lammer, Johannes, Rosmorduc, Olivier, Sangro, Bruno, Santoro, Armando, Bolondi, Luigi. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. European journal of gastroenterology & hepatology, vol.22, no.4, 391-398.
Perilongo, Giorgio, Maibach, Rudolf, Shafford, Elisabeth, Brugieres, Laurence, Brock, Penelope, Morland, Bruce, de Camargo, Beatriz, Zsiros, Jozsef, Roebuck, Derek, Zimmermann, Arthur, Aronson, Daniel, Childs, Margaret, Widing, Eva, Laithier, Veronique, Plaschkes, Jack, Pritchard, Jon, Scopinaro, Marcello, MacKinlay, Gordon, Czauderna, Piotr. Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma. The New England journal of medicine, vol.361, no.17, 1662-1670.
Philip, Philip A., Mahoney, Michelle R., Allmer, Cristine, Thomas, James, Pitot, Henry C., Kim, George, Donehower, Ross C., Fitch, Tom, Picus, Joel, Erlichman, Charles. Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.23, no.27, 6657-6663.
Pinter, Matthias, Sieghart, Wolfgang, Graziadei, Ivo, Vogel, Wolfgang, Maieron, Andreas, Königsberg, Robert, Weissmann, Adalbert, Kornek, Gabriela, Plank, Christina, Peck-Radosavljevic, Markus. Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis. The oncologist, vol.14, no.1, 70-76.
Raoul, J. L., Finn, R. S., Kang, Y. K., Park, J. W., Harris, R., Coric, V., Donica, M., Walters, I.. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.27, no.15, 4577-4577.
Sangiovanni, Angelo, Del Ninno, Ersilio, Fasani, Pierangelo, De Fazio, Cristina, Ronchi, Guido, Romeo, Raffaella, Morabito, Alberto, de Franchis, Roberto, Colombo, Massimo. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology, vol.126, no.4, 1005-1014.
Sergio, Adriana, Cristofori, Chiara, Cardin, Romilda, Pivetta, Giorgio, Ragazzi, Roberto, Baldan, Anna, Girardi, Lisa, Cillo, Umberto, Burra, Patrizia, Giacomin, Anna, Farinati, Fabio. Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness. The American journal of gastroenterology : official publication of the National Gastroenterological Association, vol.103, no.4, 914-921.
Siegel, Abby B., Cohen, Emil I., Ocean, Allyson, Lehrer, Deborah, Goldenberg, Alec, Knox, Jennifer J., Chen, Helen, Clark-Garvey, Sean, Weinberg, Alan, Mandeli, John, Christos, Paul, Mazumdar, Madhu, Popa, Elizabeta, Brown Jr, Robert S., Rafii, Shahin, Schwartz, Jonathan D.. Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.26, no.18, 2992-2998.
Thomas, Melanie B., Chadha, Romil, Glover, Katrina, Wang, Xuemei, Morris, Jeffrey, Brown, Thomas, Rashid, Asif, Dancey, Janet, Abbruzzese, James L.. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer, vol.110, no.5, 1059-1067.
Thomas, Melanie B., Morris, Jeffrey S., Chadha, Romil, Iwasaki, Michiko, Kaur, Harmeet, Lin, Elinor, Kaseb, Ahmed, Glover, Katrina, Davila, Marta, Abbruzzese, James. Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.27, no.6, 843-850.
Thomas, Melanie B.. Systemic Therapy for Hepatocellular Carcinoma. The cancer journal, vol.14, no.2, 123-127.
Thomas, Melanie B., O’Beirne, James P., Furuse, Junji, Chan, Anthony T. C., Abou-Alfa, Ghassan, Johnson, Philip. Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy. Annals of surgical oncology, vol.15, no.4, 1008-1014.
Toh, H., Chen, P., Carr, B. I., Knox, J. J., Gill, S., Steinberg, J., Carlson, D. M., Qian, J., Qin, Q., Yong, W.. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.27, no.15, 4581-4581.
Wilhelm, Scott M., Carter, Christopher, Tang, LiYa, Wilkie, Dean, McNabola, Angela, Rong, Hong, Chen, Charles, Zhang, Xiaomei, Vincent, Patrick, McHugh, Mark, Cao, Yichen, Shujath, Jaleel, Gawlak, Susan, Eveleigh, Deepa, Rowley, Bruce, Liu, Li, Adnane, Lila, Lynch, Mark, Auclair, Daniel, Taylor, Ian, Gedrich, Rich, Voznesensky, Andrei, Riedl, Bernd, Post, Leonard E., Bollag, Gideon, Trail, Pamela A.. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer research : the official organ of the American Association for Cancer Research, Inc, vol.64, no.19, 7099-7109.
Yang, Zhen Fan, Poon, Ronnie T., To, Jensen, Ho, David W., Fan, Sheung Tat. The Potential Role of Hypoxia Inducible Factor 1α in Tumor Progression after Hypoxia and Chemotherapy in Hepatocellular Carcinoma. Cancer research : the official organ of the American Association for Cancer Research, Inc, vol.64, no.15, 5496-5503.
Zhang, Bo-Heng, Yang, Bing-Hui, Tang, Zhao-You. Randomized controlled trial of screening for hepatocellular carcinoma. Journal of cancer research and clinical oncology, vol.130, no.7,
Zhu, Andrew X., Blaszkowsky, Lawrence S., Ryan, David P., Clark, Jeffrey W., Muzikansky, Alona, Horgan, Kerry, Sheehan, Susan, Hale, Kelly E., Enzinger, Peter C., Bhargava, Pankaj, Stuart, Keith. Phase II Study of Gemcitabine and Oxaliplatin in Combination With Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.24, no.12, 1898-1903.
Zhu, Andrew X., Sahani, Dushyant V., Duda, Dan G., di Tomaso, Emmanuelle, Ancukiewicz, Marek, Catalano, Onofrio A., Sindhwani, Vivek, Blaszkowsky, Lawrence S., Yoon, Sam S., Lahdenranta, Johanna, Bhargava, Pankaj, Meyerhardt, Jeffrey, Clark, Jeffrey W., Kwak, Eunice L., Hezel, Aram F., Miksad, Rebecca, Abrams, Thomas A., Enzinger, Peter C., Fuchs, Charles S., Ryan, David P., Jain, Rakesh K.. Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.27, no.18, 3027-3035.
Zhu, Andrew X., Stuart, Keith, Blaszkowsky, Lawrence S., Muzikansky, Alona, Reitberg, Donald P., Clark, Jeffrey W., Enzinger, Peter C., Bhargava, Pankaj, Meyerhardt, Jeffrey A., Horgan, Kerry, Fuchs, Charles S., Ryan, David P.. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer, vol.110, no.3, 581-589.
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.